TipRanks
Iovance Biotherapeutics Inc (DE:2LB)
FRANKFURT:2LB
Germany Market
2LB
Iovance Biotherapeutics
RESEARCH TOOLSreports

Iovance Biotherapeutics (2LB) Stock Forecast & Price Target

19 Followers
See the Price Targets and Ratings of:

2LB Analyst Ratings

Moderate Buy
7Ratings
Moderate Buy
5 Buy
2 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Iovance
Biotherapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2LB Stock 12 Month Forecast

Average Price Target

€8.21
▲(12.45% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Iovance Biotherapeutics in the last 3 months. The average price target is €8.21 with a high forecast of €13.06 and a low forecast of €5.22. The average price target represents a 12.45% change from the last price of €7.30.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","7":"€7","14":"€14","3.5":"€3.5","10.5":"€10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13.05905835,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€13.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.208550962857144,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€8.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.22362334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€5.22</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.5,7,10.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.88,7.35531218076923,7.830624361538462,8.305936542307693,8.781248723076923,9.256560903846154,9.731873084615385,10.207185265384616,10.682497446153846,11.157809626923077,11.633121807692309,12.108433988461538,12.58374616923077,{"y":13.05905835,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.88,6.9821962279120875,7.084392455824176,7.186588683736264,7.288784911648352,7.39098113956044,7.493177367472528,7.595373595384616,7.697569823296704,7.799766051208792,7.90196227912088,8.004158507032969,8.106354734945056,{"y":8.208550962857144,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.88,6.752586410769231,6.625172821538461,6.4977592323076925,6.370345643076923,6.242932053846154,6.115518464615384,5.988104875384615,5.860691286153846,5.733277696923077,5.605864107692307,5.478450518461538,5.351036929230769,{"y":5.22362334,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.968,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.002,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.167,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.233,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.014,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.805,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.405,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.925,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.88,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€13.06Average Price Target€8.21Lowest Price Target€5.22
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on DE:2LB
Etzer Darout
Barclays
Barclays
€11.32→€13.06
Buy
78.89%
Upside
Reiterated
09/17/26
Iovance Biotherapeutics (IOVA) Receives a Buy from Barclays
TD Cowen Analyst forecast on DE:2LB
Nicholas Lorusso
TD Cowen
TD Cowen
€6.09→€8.71
Buy
19.26%
Upside
Assigned
08/25/26
Lorusso Boosts Iovance Biotherapeutics Price Target to $10 on Strong Amtagvi Momentum and Operational Upside, Reaffirms Buy Rating
UBS Analyst forecast on DE:2LB
David Dai
UBS
UBS
€3.48→€6.09
Hold
-16.52%
Downside
Assigned
08/20/26
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), CervoMed (NASDAQ: CRVO) and Korro Bio (NASDAQ: KRRO)
Mizuho Securities Analyst forecast on DE:2LB
Salim Syed
Mizuho Securities
Mizuho Securities
€8.71→€9.58
Buy
31.19%
Upside
Reiterated
08/17/26
Mizuho Securities Remains a Buy on Iovance Biotherapeutics (IOVA)
Robert W. Baird Analyst forecast on DE:2LB
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
€3.48→€5.22
Hold
-28.44%
Downside
Reiterated
08/07/26
Iovance Biotherapeutics price target raised to $6 from $4 at BairdIovance Biotherapeutics price target raised to $6 from $4 at Baird
Citizens JMP Analyst forecast on DE:2LB
Reni Benjamin
Citizens JMP
Citizens JMP
€4.35→€6.96
Buy
-4.59%
Downside
Reiterated
08/07/26
Iovance Biotherapeutics price target raised to $8 from $5 at CitizensIovance Biotherapeutics price target raised to $8 from $5 at Citizens
H.C. Wainwright Analyst forecast on DE:2LB
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
€7.84
Buy
7.33%
Upside
Reiterated
08/06/26
Iovance: Strong AMTAGVI Execution and Global Expansion Support Buy Rating with Unchanged $9 Price Target
Chardan Capital Analyst forecast on DE:2LB
Geulah Livshits
Chardan Capital
Chardan Capital
€12.19
Buy
66.97%
Upside
Reiterated
05/07/26
Iovance Biotherapeutics price target lowered to $14 from $16 at ChardanIovance Biotherapeutics price target lowered to $14 from $16 at Chardan
Wells Fargo Analyst forecast on DE:2LB
Yanan Zhu
Wells Fargo
Wells Fargo
€12.19
Buy
66.97%
Upside
Reiterated
02/25/26
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), BioMarin Pharmaceutical (NASDAQ: BMRN) and Kiniksa Pharmaceuticals (NASDAQ: KNSA)
Truist Financial Analyst forecast on DE:2LB
Asthika Goonewardene
Truist Financial
Truist Financial
―
Hold
―
Reiterated
02/25/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (NASDAQ: IOVA), Erasca (NASDAQ: ERAS) and Tempus AI, Inc. Class A (NASDAQ: TEM)
Goldman Sachs Analyst forecast on DE:2LB
Andrea Newkirk
Goldman Sachs
Goldman Sachs
€1.31→€1.74
Sell
-76.15%
Downside
Reiterated
02/05/26
Iovance Biotherapeutics price target raised to $2 from $1.50 at Goldman SachsIovance Biotherapeutics price target raised to $2 from $1.50 at Goldman Sachs
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on DE:2LB
Etzer Darout
Barclays
Barclays
€11.32→€13.06
Buy
78.89%
Upside
Reiterated
09/17/26
Iovance Biotherapeutics (IOVA) Receives a Buy from Barclays
TD Cowen Analyst forecast on DE:2LB
Nicholas Lorusso
TD Cowen
TD Cowen
€6.09→€8.71
Buy
19.26%
Upside
Assigned
08/25/26
Lorusso Boosts Iovance Biotherapeutics Price Target to $10 on Strong Amtagvi Momentum and Operational Upside, Reaffirms Buy Rating
UBS Analyst forecast on DE:2LB
David Dai
UBS
UBS
€3.48→€6.09
Hold
-16.52%
Downside
Assigned
08/20/26
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), CervoMed (NASDAQ: CRVO) and Korro Bio (NASDAQ: KRRO)
Mizuho Securities Analyst forecast on DE:2LB
Salim Syed
Mizuho Securities
Mizuho Securities
€8.71→€9.58
Buy
31.19%
Upside
Reiterated
08/17/26
Mizuho Securities Remains a Buy on Iovance Biotherapeutics (IOVA)
Robert W. Baird Analyst forecast on DE:2LB
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
€3.48→€5.22
Hold
-28.44%
Downside
Reiterated
08/07/26
Iovance Biotherapeutics price target raised to $6 from $4 at BairdIovance Biotherapeutics price target raised to $6 from $4 at Baird
Citizens JMP Analyst forecast on DE:2LB
Reni Benjamin
Citizens JMP
Citizens JMP
€4.35→€6.96
Buy
-4.59%
Downside
Reiterated
08/07/26
Iovance Biotherapeutics price target raised to $8 from $5 at CitizensIovance Biotherapeutics price target raised to $8 from $5 at Citizens
H.C. Wainwright Analyst forecast on DE:2LB
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
€7.84
Buy
7.33%
Upside
Reiterated
08/06/26
Iovance: Strong AMTAGVI Execution and Global Expansion Support Buy Rating with Unchanged $9 Price Target
Chardan Capital Analyst forecast on DE:2LB
Geulah Livshits
Chardan Capital
Chardan Capital
€12.19
Buy
66.97%
Upside
Reiterated
05/07/26
Iovance Biotherapeutics price target lowered to $14 from $16 at ChardanIovance Biotherapeutics price target lowered to $14 from $16 at Chardan
Wells Fargo Analyst forecast on DE:2LB
Yanan Zhu
Wells Fargo
Wells Fargo
€12.19
Buy
66.97%
Upside
Reiterated
02/25/26
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), BioMarin Pharmaceutical (NASDAQ: BMRN) and Kiniksa Pharmaceuticals (NASDAQ: KNSA)
Truist Financial Analyst forecast on DE:2LB
Asthika Goonewardene
Truist Financial
Truist Financial
―
Hold
―
Reiterated
02/25/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (NASDAQ: IOVA), Erasca (NASDAQ: ERAS) and Tempus AI, Inc. Class A (NASDAQ: TEM)
Goldman Sachs Analyst forecast on DE:2LB
Andrea Newkirk
Goldman Sachs
Goldman Sachs
€1.31→€1.74
Sell
-76.15%
Downside
Reiterated
02/05/26
Iovance Biotherapeutics price target raised to $2 from $1.50 at Goldman SachsIovance Biotherapeutics price target raised to $2 from $1.50 at Goldman Sachs
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ZVRAZevra Therapeutics
ELVNEnliven Therapeutics
DFTXDefinium Therapeutics
AMRXAmneal Pharmaceuticals
DNTHDianthus Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Iovance Biotherapeutics

3 Months
Joseph PantginisH.C. Wainwright
Success Rate
13/14 ratings generated profit
93%
Average Return
+33.06%
Copying Joseph Pantginis's trades and holding each position for 3 Months would result in 92.86% of your transactions generating a profit, with an average return of +33.06% per trade.
1 Year
Etzer DaroutBarclays
Success Rate
12/12 ratings generated profit
100%
Average Return
+151.54%
Copying Etzer Darout's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +151.54% per trade.
2 Years
Joseph PantginisH.C. Wainwright
Success Rate
14/14 ratings generated profit
100%
Average Return
+304.96%
Copying Joseph Pantginis's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +304.96% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2LB Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
8
11
9
7
3
Buy
1
1
1
4
5
Hold
1
0
0
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
12
10
13
10
In the current month, 2LB has received 8 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 2LB average Analyst price target in the past 3 months is 8.21.
Each month's total comprises the sum of three months' worth of ratings.

2LB Financial Forecast

2LB Earnings Forecast

Next quarter’s earnings estimate for 2LB is -€0.08 with a range of -€0.10 to -€0.07. The previous quarter’s EPS was -€0.09. 2LB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 2LB has Performed in-line its overall industry.
Next quarter’s earnings estimate for 2LB is -€0.08 with a range of -€0.10 to -€0.07. The previous quarter’s EPS was -€0.09. 2LB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 2LB has Performed in-line its overall industry.

2LB Sales Forecast

Next quarter’s sales forecast for 2LB is €94.41M with a range of €86.99M to €102.03M. The previous quarter’s sales results were €85.15M. 2LB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 2LB has Performed in-line its overall industry.
Next quarter’s sales forecast for 2LB is €94.41M with a range of €86.99M to €102.03M. The previous quarter’s sales results were €85.15M. 2LB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 2LB has Performed in-line its overall industry.

2LB Stock Forecast FAQ

What is DE:2LB’s average 12-month price target, according to analysts?
Based on analyst ratings, Iovance Biotherapeutics Inc’s 12-month average price target is 8.21.
    What is DE:2LB’s upside potential, based on the analysts’ average price target?
    Iovance Biotherapeutics Inc has 12.45% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Iovance Biotherapeutics Inc a Buy, Sell or Hold?
          Iovance Biotherapeutics Inc has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Iovance Biotherapeutics Inc’s share price target?
            The average share price target for Iovance Biotherapeutics Inc is 8.21. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €13.06 ,and the lowest forecast is €5.22. The average share price target represents 12.45% Increase from the current price of €7.3.
              What do analysts say about Iovance Biotherapeutics Inc?
              Iovance Biotherapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of Iovance Biotherapeutics Inc?
                To buy shares of DE:2LB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.